-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the 16th, Shanghai RAAS issued an announcement stating that its wholly-owned subsidiary, Human Prothrombin Complex, had recently received the "Drug Registration Certificate" issued by the State Drug Administration
Human prothrombin complex is mainly used to treat congenital and acquired coagulation factor Ⅱ, Ⅶ, Ⅸ, Ⅹ deficiencies including coagulation factor Ⅱ, Ⅶ, Ⅸ, Ⅹ deficiencies including hemophilia B; anticoagulant overdose, Vitamin K deficiency; coagulation disorder caused by liver disease; during disseminated intravascular coagulation (DIC), coagulation factors Ⅱ, Ⅶ, Ⅸ, Ⅹ are consumed in large quantities and can be used after heparinization; caused by various reasons Patients with prothrombin time prolonged and intended for surgery, but may not be effective for patients with coagulation factor V deficiency; treatment of bleeding symptoms in patients with hemophilia A who have produced factor VIII inhibitors; reversal of bleeding induced by coumarin anticoagulants